| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥8084.5B | ¥8269.0B | -2.2% |
| Operating Income | ¥588.8B | ¥850.8B | -30.8% |
| Ordinary Income | ¥515.1B | ¥814.8B | -36.8% |
| Net Income | ¥383.0B | ¥671.2B | -42.9% |
| ROE | 5.1% | 8.6% | - |
FY2025 full-year results: Revenue 808.4B yen (YoY -2.2%), Operating Income 58.9B yen (YoY -30.8%), Ordinary Income 51.5B yen (YoY -36.8%), Net Income 38.3B yen (YoY -42.9%). The company experienced significant profit deterioration despite modest revenue decline. Operating margin contracted sharply to 7.3% from prior year's 10.3%, driven by segment profit erosion and increased corporate costs. Extraordinary losses totaling 29.6B yen in impairment charges substantially impacted bottom-line results. The effective tax rate reached 74.5%, creating additional earnings pressure. Despite profit challenges, operating cash flow generation remained robust at 98.6B yen, though free cash flow compressed to minimal levels at 0.5B yen due to substantial capital expenditure of 94.2B yen. Balance sheet fundamentals remain solid with equity ratio of 57.9% and current ratio of 253.4%, though working capital expansion in inventory and receivables warrants attention.
Revenue decreased 2.2% YoY to 808.4B yen, reflecting challenging market conditions across key segments. By segment, Vinyl Acetate generated 404.5B yen with operating income of 62.5B yen, representing the core earnings pillar though profit declined 28.6% from prior year's 87.6B yen. Functional Materials recorded sales of 206.9B yen with operating income of 10.8B yen, down 16.4% in profit. Isoprene segment posted 80.4B yen in sales but incurred operating loss of 4.9B yen, improved from prior loss of 9.5B yen yet remaining in negative territory. Fibers and Textiles achieved 60.7B yen in sales with 2.6B yen operating profit, showing recovery from 1.2B yen prior year. Trading segment contributed 68.8B yen in revenue and 6.0B yen in operating profit. Geographically, US sales increased to 188.1B yen from 183.5B yen, while Japan declined to 161.8B yen from 172.1B yen, China softened to 119.7B yen from 123.6B yen, and Europe contracted to 203.7B yen from 206.5B yen. Operating profit declined substantially due to combination of gross margin compression and increase in unallocated corporate costs to 22.2B yen from 18.5B yen, primarily basic research expenses. Impairment losses totaling 29.6B yen were recognized, concentrated in Isoprene segment at 25.6B yen, creating significant non-recurring drag. The gap between ordinary income (51.5B yen) and operating income (58.9B yen) reflects net non-operating loss of 7.4B yen, comprising interest expenses of 2.8B yen and forex impacts. Net income declined 42.9% to 38.3B yen, amplified by extraordinary losses of 31.7B yen and effective tax burden of 124.0B yen on pre-tax income of 19.8B yen, indicating substantial deferred tax valuation adjustments or other tax factors beyond normal rates. This represents a revenue down, profit down scenario with profit deterioration exceeding revenue decline magnitude.
Vinyl Acetate segment represents the core business with 404.5B yen in sales (49.2% of total reportable segment revenue) and 62.5B yen in operating income, maintaining operating margin of 15.5% despite 28.6% profit decline. This segment produces functional resins and films including Poval, PVB, and EVOH resin under the Eval brand. Isoprene segment recorded 80.4B yen in revenue but generated operating loss of 4.9B yen (-6.1% margin), improving from prior loss of 9.5B yen yet remaining structurally challenged. The segment absorbed 25.6B yen in impairment charges during the period. Functional Materials contributed 206.9B yen in sales with 10.8B yen operating income (5.2% margin), experiencing 16.4% profit decline from prior 12.9B yen. This segment encompasses methacrylic resins, medical products, and activated carbon. Fibers and Textiles generated 60.7B yen in revenue and 2.6B yen operating profit (4.3% margin), demonstrating recovery from prior year's 1.2B yen. Trading segment posted 68.8B yen in sales and 6.0B yen in operating income (8.8% margin), maintaining relatively stable contribution. Margin disparity is evident with Vinyl Acetate sustaining double-digit profitability while Functional Materials, Fibers, and Trading operate in mid-to-high single digits, and Isoprene requiring structural turnaround to achieve profitability.
[Profitability] ROE stands at 1.0% for the current period, substantially below the company's 3-year historical average reflecting depressed net income from extraordinary items and tax burdens. Operating margin contracted to 7.3% from prior 10.3%, representing 300 basis point deterioration. Net profit margin compressed to 0.9% from prior 8.1%, evidencing the substantial impact of non-recurring impairments and elevated tax burden. EBITDA margin of 17.8% indicates underlying operational cash generation capacity remains intact. [Cash Quality] Cash and deposits total 104.1B yen, providing coverage ratio of 2.31 times against short-term debt of 45.1B yen, indicating strong liquidity positioning. However, working capital expanded with accounts receivable increasing to 178.3B yen and inventory rising to 178.0B yen, creating cash conversion cycle concerns. Days Inventory Outstanding reached 112.5 days and Days Sales Outstanding extended to 83.8 days, evidencing working capital management challenges. [Investment Efficiency] Asset turnover ratio of 0.62 reflects modest capital intensity typical of chemical manufacturing. ROIC calculated at 3.5% falls significantly short of capital cost thresholds, warranting strategic review of capital deployment. [Financial Health] Equity ratio maintains solid position at 57.9%, demonstrating conservative capital structure. Current ratio of 253.4% and debt-to-equity ratio of 0.25 indicate limited financial leverage and ample short-term liquidity buffers. Interest-bearing debt totals 191.3B yen representing manageable leverage at 1.33 times EBITDA. Interest coverage ratio of 21.0 times provides substantial debt servicing cushion.
Operating cash flow generation totaled 98.6B yen, demonstrating strong cash conversion capability despite profit challenges, representing 13.2 times net income though this ratio is distorted by depressed earnings base. Depreciation and amortization of 84.7B yen provided substantial non-cash addback to operating activities. Working capital movements reflected pressure from inventory accumulation and receivables expansion, though the absolute operating cash flow level remained robust. Investing cash flow consumed 98.1B yen, predominantly allocated to capital expenditures on property, plant, equipment and intangible assets totaling 94.2B yen. This investment intensity at 11.7% of revenue signals ongoing capacity expansion and modernization initiatives. Free cash flow compressed to 0.5B yen after these capital deployments, constraining financial flexibility. Financing cash flow showed outflow of 26.1B yen, incorporating dividend payments of 17.7B yen and share repurchase execution of 30.0B yen totaling 47.7B yen in shareholder returns. Short-term borrowings increased 21.3B yen from 23.9B yen to 45.1B yen, partially offsetting shareholder return funding requirements. Cash position decreased modestly to 104.1B yen from prior 106.9B yen, maintaining adequate liquidity reserves despite substantial capital allocation activities.
Ordinary income of 51.5B yen compared to operating income of 58.9B yen reflects net non-operating expense of 7.4B yen. Non-operating income composition includes equity method investment income of 0.7B yen and interest and dividend income contributing modest amounts, offset by interest expense of 2.8B yen and foreign exchange adjustments. Non-operating items represent approximately 0.9% of revenue, remaining within normal operational parameters. Extraordinary items totaling 31.7B yen loss comprised primarily 29.6B yen in impairment charges concentrated in Isoprene segment assets, representing clearly identifiable non-recurring adjustments. The divergence between pre-tax income of 19.8B yen and net income of 38.3B yen warrants examination, as tax expense appears negative at -18.5B yen, suggesting deferred tax asset recognition or other tax benefits despite the elevated effective tax rate commentary in operating context. Operating cash flow of 98.6B yen substantially exceeds reported net income, though this comparison is influenced by large non-cash impairment charges and working capital movements. Core earnings quality from recurring operations appears sound based on cash generation capability, while reported net income reflects substantial non-recurring adjustments warranting normalization for underlying performance assessment.
Full-year FY2025 guidance projects revenue of 850.0B yen, operating income of 70.0B yen, ordinary income of 64.0B yen, and net income of 40.0B yen with annual dividend of 32.0 yen per share. Actual results show revenue achievement rate of 95.1%, operating income achievement of 84.1%, ordinary income achievement of 80.5%, and net income accomplishment of 95.8%. The company revised guidance upward during the fiscal year, with projected YoY changes indicating revenue growth of 5.1%, operating income increase of 18.9%, and ordinary income expansion of 24.2%. The achievement rates suggest fourth quarter performance fell short of initial trajectory expectations, particularly at operating income level with approximately 16% shortfall. The guidance assumes recovery in segment profitability and normalization from extraordinary items, with net income guidance approximating actual results indicating management anticipated the impairment impacts. The modest revenue guidance shortfall of 4.9% suggests demand environment remained challenged through period end. Operating income guidance gap of approximately 11.2B yen indicates either slower margin recovery or higher cost structure persistence than initially projected.
Annual dividend totaled 54.0 yen per share comprising interim dividend of 27.0 yen and year-end dividend of 27.0 yen, maintaining stable distribution from prior year levels. Total dividend payments amounted to 17.7B yen. Calculated payout ratio reaches 222.7% based on parent company attributable net income of 7.5B yen, indicating dividend distribution substantially exceeded reported earnings, though this reflects extraordinary loss impacts on denominator. XBRL reported payout ratio of 0.6% suggests methodology differences in calculation basis. The company executed share repurchase program totaling 30.0B yen during the period, demonstrating strong shareholder return commitment. Combined dividends and buybacks total 47.7B yen, representing total return ratio exceeding 600% relative to parent attributable net income, though this metric is distorted by depressed earnings base from non-recurring items. Against free cash flow of only 0.5B yen, the total shareholder return of 47.7B yen indicates returns funded from balance sheet cash reserves rather than current period generation. FY2025 guidance indicates projected dividend of 32.0 yen per share, suggesting reduction from current 54.0 yen level, aligning distribution policy with normalized earnings trajectory.
Market demand volatility and pricing pressure in key chemical and materials segments represent primary revenue risk, as evidenced by YoY sales decline and margin compression across segments. Petrochemical feedstock cost fluctuations and inability to pass through pricing could further pressure operating margins, particularly acute in commodity-exposed segments. Isoprene segment structural challenges evidenced by 25.6B yen impairment charge and continued operating losses indicate potential for additional asset write-downs or restructuring costs if turnaround initiatives fail to restore profitability. Working capital management deterioration with inventory reaching 178.0B yen and receivables 178.3B yen creates obsolescence risk and potential for additional write-downs if demand remains soft, while extended cash conversion cycle constrains financial flexibility.
[Industry Position] (Reference - Proprietary Analysis) The company's operating margin of 7.3% represents compression from historical levels and likely trails specialty chemical peers who typically maintain double-digit operating margins in favorable conditions. Net profit margin of 0.9% falls substantially below normalized levels due to extraordinary items, though underlying EBITDA margin of 17.8% suggests operational leverage remains within industry parameters. ROE of 1.0% significantly underperforms chemical sector medians typically ranging 8-12%, though current year reflects non-recurring distortions. The company's equity ratio of 57.9% demonstrates conservative balance sheet positioning relative to industry, where specialty chemical manufacturers often operate with 40-50% equity ratios. Debt-to-EBITDA of 1.33 times indicates below-average leverage compared to industry median leverage of 2.0-2.5 times, providing substantial financial flexibility for capital deployment. Revenue growth of -2.2% trails industry conditions where specialty materials segments have shown resilience, suggesting company-specific market share or product mix challenges beyond cyclical factors.
First, the substantial impairment charge of 29.6B yen concentrated in Isoprene segment signals management recognition of structural challenges requiring strategic repositioning, with loss elimination remaining critical priority for consolidated profitability restoration. Second, robust operating cash flow generation of 98.6B yen despite profit challenges demonstrates underlying business resilience and cash conversion capability, though working capital expansion from inventory buildup and receivables extension indicates operational efficiency deterioration requiring management attention. Third, shareholder return commitment evidenced by 30.0B yen buyback and 17.7B yen dividend distribution totaling 47.7B yen against minimal free cash flow of 0.5B yen reflects balance sheet deployment rather than earning-based sustainability, with projected dividend reduction to 32.0 yen per share in FY2025 guidance suggesting policy recalibration toward earnings alignment.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.